Finance

Lists
Why is NRIX down 2.30%?
Dive Deeper
NRIX:NASDAQ
Nurix Therapeutics Inc
$23.33
-2.30%
(-0.55) 1D
Sep 24, 12:13:59 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NRIX...
Open
$23.76
High
$23.93
Low
$23.03
Mkt. cap
2.42B
Avg. vol.
1.30M
Volume
340.24K
52-wk high
$28.23
52-wk low
$8.22
EPS
-$3.45
Beta
1.80
Shares outstanding
103.78M
No. of employees
317
Open
$23.76
High
$23.93
Low
$23.03
Mkt. cap
2.42B
Avg. vol.
1.30M
Volume
340.24K
52-wk high
$28.23
52-wk low
$8.22
EPS
-$3.45
Beta
1.80
Shares outstanding
103.78M
No. of employees
317
News stories
From web sources and news partners
About Nurix Therapeutics Inc
CEO-
Employees317
Founded2009
HeadquartersBrisbane, California, United States
SectorBiotechnology
Websitenurixtx.com
Analyst ratings
Based on 11 analysts giving stock ratings to NRIX in the past 3 months
Strong buy
Buy
10
Hold
1
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for NRIX in the last 3 months.
Highest
Current $23.33
$45.00 (+92.88%)
Average
$34.27 (+46.89%)
Lowest
$25.00 (+7.16%)
Analyst
Recommendation
Action
Price target
Projected
Date
Derek Archila
Wells Fargo
Hold
Maintained
$25.00
+7.2%
09/01/2026
Brian Abrahams
RBC Capital
Buy
Reiterated
$36.00
+54.3%
08/10/2026
Gil Blum
Needham
Buy
Maintained
$34.00
+45.7%
08/04/2026
Terence Flynn
Morgan Stanley
Buy
Reiterated
$38.00
+62.9%
07/28/2026
David Dai
UBS
Buy
Reiterated
$31.00
+32.9%
07/22/2026
Joseph Catanzaro
Mizuho Securities
Buy
Maintained
$34.00
+45.7%
07/13/2026
Kostas Biliouris
Oppenheimer
Buy
Maintained
$28.00
+20%
07/10/2026
Nevin Varghese
RBC Capital
Buy
Reiterated
$33.00
+41.4%
07/09/2026
Stephen Willey
Stifel Nicolaus
Buy
Reiterated
$40.00
+71.5%
07/10/2026
Gregory Renza
Truist Financial
Buy
Reiterated
$34.00
+45.7%
07/10/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$34.00
+45.7%
07/10/2026
Roger Song
Jefferies
Buy
Maintained
$45.00
+92.9%
07/08/2026
Jeet Mukherjee
BTIG
Buy
Reiterated
$32.00
+37.2%
07/01/2026
Tessa Romero
J.P. Morgan
Buy
Maintained
-
-
06/11/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$28.00
+20%
05/13/2026
Biren Amin
Piper Sandler
Buy
Maintained
$35.00
+50%
05/13/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Aug 2025
Nov 2025
Feb 2026
May 2026
Revenue
7.89M
13.58M
6.25M
9.04M
Cost of goods sold
86.12M
83.02M
84.14M
87.65M
Cost of revenue
86.12M
83.02M
84.14M
87.65M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13.16M
13.65M
14.61M
15.59M
Operating expense
13.16M
13.65M
14.61M
15.59M
Total operating expenses
99.28M
96.67M
98.75M
103.25M
Operating income
-91.38M
-83.10M
-92.50M
-94.20M
Other non operating income
-
-
-
-
EBT including unusual items
-86.42M
-78.22M
-87.17M
-89.81M
EBT excluding unusual items
-86.42M
-78.22M
-87.17M
-89.81M
Income tax expense
-
-
-
-271.00K
Effective tax rate
-
-
-
0.30%
Other operating expenses
-
-
-
-
Net income
-86.42M
-78.22M
-87.17M
-89.54M
Net profit margin
-1,094.77%
-576.13%
-1,394.34%
-990.10%
Earnings per share
-1.03
-0.82
-0.79
-0.81
Interest and investment income
4.96M
4.87M
5.32M
4.40M
Interest expense
-
-
-
-
Net interest expenses
4.96M
4.87M
5.32M
4.40M
Depreciation and amortization charges
-
-
-
-
EBITDA
-89.36M
-81.58M
-90.30M
-91.95M
Gain or loss from assets sale
-
89.00K
160.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps